Insights

Gathering insights about NetIX…

Similar companies to NetIX

NetIX Tech Stack

NetIX uses 8 technology products and services including cdnjs, Cloudflare, Slick, and more. Explore NetIX's tech stack below.

cdnjs
Content Delivery Network
Cloudflare
Content Management System
Slick
Javascript Libraries
jQuery
Javascript Libraries
reCAPTCHA
Security
Bootstrap
UI Frameworks
Apache
Web Servers
BDOW
Widgets

Media & News

Onco-Innovations Appoints Jared Rushton to Board of Directors
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company"),is pleased to announce the appointment of Mr. Jared Rushton to its Board of Directors, effective immediately.
Oct 30, 2025 | www.accessnewswire.com
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million (the “Financing Transaction”). Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investors. The Series D Preferred Stock are initially convertible into an aggregate of 4,362,827 shares of Common Stock, subject to certain anti-dilution adjustments. The Warrants will have an initial exercise price of $3.6896 per share, subject to certain anti-dilution adjustments, and are exercisable beginning on the issuance date (the "Initial Exercisability Date") and expiring on the third anniversary of the Initial Exercisability Date.
Sep 26, 2025 | www.globenewswire.com
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025.
Sep 26, 2025 | www.globenewswire.com
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden.
Sep 22, 2025 | www.globenewswire.com
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden.
Sep 22, 2025 | www.globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Onconetix, Inc. (NASDAQ: ONCO ) related to its merger with Ocuvex Therapeutics, Inc. Upon completion of the proposed transaction, each share of Ocuvex will be exchanged for a number of Onconetix shares based on a defined exchange ratio, resulting in Ocuvex shareholders owning approximately 90% of the combined company and Onconetix shareholders owning approximately 10%. Is it a fair deal?
Jul 17, 2025 | www.globenewswire.com
ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Onconetix, Inc. (NASDAQ: ONCO) and Ocuvex Therapeutics, Inc. is fair to Onconetix shareholders. Upon completion of the proposed transaction, Onconetix shareholders will own 10% of the combined company. Halper Sadeh encourages Onconetix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@hal.
Jul 16, 2025 | www.businesswire.com

NetIX's Email Address Formats

NetIX uses at least 1 format(s):

NetIX Email Formats	Example	Percentage
FLast@netix.net	JDoe@netix.net	50%
FLast@netix.net	JDoe@netix.net	50%

Frequently Asked Questions

Where is NetIX's headquarters located?

NetIX's main headquarters is located at 20A Andrey Saharov Blvd., Sofia, 1784, BG. The company has employees across 3 continents, including EuropeSouth AmericaNorth America.

What is NetIX's stock symbol?

NetIX is a publicly traded company; the company's stock symbol is ONCO.

What is NetIX's official website and social media links?

NetIX's official website is netix.net and has social profiles on LinkedIn Crunchbase.

What is NetIX's NAICS code?

NetIX's NAICS code is 517 - Telecommunications.

How many employees does NetIX have currently?

As of October 2025, NetIX has approximately 51 employees across 3 continents, including EuropeSouth AmericaNorth America. Key team members include Chief Technical Officer: Y. K.Founder: N. D.Founder: A. T.. Explore NetIX's employee directory with LeadIQ.

What industry does NetIX belong to?

NetIX operates in the Telecommunications industry.

What technology does NetIX use?

NetIX's tech stack includes cdnjsCloudflareSlickjQueryreCAPTCHABootstrapApacheBDOW.

What is NetIX's email format?

NetIX's email format typically follows the pattern of FLast@netix.net. Find more NetIX email formats with LeadIQ.

When was NetIX founded?

NetIX was founded in 2012.

NetIX

TelecommunicationsBulgaria51-200 Employees

About NetIX

Our next-generation network accelerates the Internet; we connect content creators with users faster, cheaper, and more directly than ever.

Our network stretches across more than 220+ global data centres in 100 cities from 65 countries. It connects our 200+ members to content from 10,000+ visible networks and 30+ Internet Exchanges.

NetIX offers the best possible Internet connectivity: our members can directly exchange traffic with peers, giving their end-users faster page-load times on 90% of the most popular sites.

Our members include Internet service providers, broadcasters, telecoms operators, and content delivery networks - all the peers your tenants need to access!

Get in touch with our expert team: contact@netix.net

Company Overview

Headquarters: 20A Andrey Saharov Blvd., Sofia, 1784, BG
Website: netix.net
Stock Symbol: ONCO
NAICS Code: 517 - Telecommunications
Founded: 2012
Employees: 51-200

Media & News

Funding & Financials

$1M$10M
NetIX's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
NetIX's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to NetIX

TechWise

Powertech

Dataprobe

CORETECH

Intellectix

SMARTTECH

NetIX Tech Stack

Media & News

Onco-Innovations Appoints Jared Rushton to Board of Directors

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders

NetIX's Email Address Formats

Frequently Asked Questions

Where is NetIX's headquarters located?

What is NetIX's stock symbol?

What is NetIX's official website and social media links?

What is NetIX's NAICS code?

How many employees does NetIX have currently?

What industry does NetIX belong to?

What technology does NetIX use?

What is NetIX's email format?

When was NetIX founded?

NetIX

Company Overview

Media & News

Onco-Innovations Appoints Jared Rushton to Board of Directors

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?